title: Pretransplant administration of imatinib for allo-HSCT in patients with BCR-ABL-positive acute lymphoblastic leukemia.
abstract: We aimed to evaluate the impact of pretransplant imatinib administration on the outcome of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in adults with Philadelphia chromosome-positive (Ph(+)) acute lymphoblastic leukemia (ALL). We retrospectively analyzed 738 patients with Ph(+) ALL that underwent allo-HSCT between 1990 and 2010 using data from the Transplant Registry Unified Management Program of the Japan Society of Hematopoietic Cell Transplantation. We compared the allo-HSCT outcomes between 542 patients who received imatinib before allo-HSCT during the initial complete remission period (imatinib cohort) and 196 patients who did not receive imatinib (non-imatinib cohort). The 5-year overall survival after allo-HSCT was significantly higher in the imatinib cohort than in the non-imatinib cohort (59% vs 38%; 95% confidence interval [CI], 31-45%; P < .001). Multivariate analysis indicated that pretransplant imatinib administration had beneficial effects on overall survival (hazard ratio [HR], 0.57; 95% CI, 0.42-0.77; P < .001), relapse (HR, 0.66; 95% CI, 0.43-0.99; P = .048), and nonrelapse mortality (HR, 0.55; 95% CI, 0.37-0.83; P = .005). In conclusion, our study showed that imatinib administration before allo-HSCT had advantageous effects on the clinical outcomes of allo-HSCT in patients with Ph(+) ALL.
authors.affiliation: Department of Hematology, Fujita Health University Hospital, Toyoake, Japan;
authors.forename: Shuichi
authors.initials: S
authors.lastname: Mizuta
authors.forename: Keitaro
authors.initials: K
authors.lastname: Matsuo
authors.forename: Satoshi
authors.initials: S
authors.lastname: Nishiwaki
authors.forename: Kiyotoshi
authors.initials: K
authors.lastname: Imai
authors.forename: Heiwa
authors.initials: H
authors.lastname: Kanamori
authors.forename: Kazuteru
authors.initials: K
authors.lastname: Ohashi
authors.forename: Takahiro
authors.initials: T
authors.lastname: Fukuda
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Onishi
authors.forename: Koichi
authors.initials: K
authors.lastname: Miyamura
authors.forename: Satoshi
authors.initials: S
authors.lastname: Takahashi
authors.forename: Makoto
authors.initials: M
authors.lastname: Onizuka
authors.forename: Yoshiko
authors.initials: Y
authors.lastname: Atsuta
authors.forename: Ritsuro
authors.initials: R
authors.lastname: Suzuki
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Morishima
authors.forename: Koji
authors.initials: K
authors.lastname: Kato
authors.forename: Hisashi
authors.initials: H
authors.lastname: Sakamaki
authors.forename: Junji
authors.initials: J
authors.lastname: Tanaka
mesh_terms: D000293:Adolescent; D000328:Adult; D064591:Allografts; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001549:Benzamides / Q000008:administration & dosage*; D003131:Combined Modality Therapy; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D000068877:Imatinib Mesylate; D053208:Kaplan-Meier Estimate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000401:mortality / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000008:administration & dosage*; D016016:Proportional Hazards Models; D011743:Pyrimidines / Q000008:administration & dosage*; D012189:Retrospective Studies; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate